F-18-OMFD-PET for Radiotherapy Treatment Planning and Evaluation of Early Therapy Response

This study has been terminated.
Sponsor:
Collaborator:
Advanced Biochemical Compounds GmbH
Information provided by:
Technische Universität Dresden
ClinicalTrials.gov Identifier:
NCT00180193
First received: September 13, 2005
Last updated: August 25, 2009
Last verified: August 2009
  Purpose

The purpose of this study is to monitor the amino acid uptake of brain tumors, before and during radiotherapy, with positron emission tomography.


Condition Phase
Brain Tumor
Phase 2

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: F-18-OMFD-PET for Radiotherapy Treatment Planning and Evaluation of Early Therapy Response

Resource links provided by NLM:


Further study details as provided by Technische Universität Dresden:

Estimated Enrollment: 40
Study Start Date: December 2003
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

OMFD-PET of all patients after subtotal resection or biopsy of malignant glioma was evaluated.

Criteria

Inclusion Criteria:

  • Brain tumor
  • Radiation therapy indicated
  • Written consent

Exclusion Criteria:

  • Pregnancy
  • Mental impairment
  • Drug/alcohol abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00180193

Locations
Germany
Department of Nuclear Medicine
Dresden, Germany, 01307
Sponsors and Collaborators
Technische Universität Dresden
Advanced Biochemical Compounds GmbH
Investigators
Principal Investigator: Joerg Kotzerke, MD Department of Nuclear Medicine
  More Information

No publications provided

Responsible Party: Prof. Dr. med. Jörg Kotzerke, Klinik und Poliklinik für Nuklearmedizin
ClinicalTrials.gov Identifier: NCT00180193     History of Changes
Other Study ID Numbers: ABX-OMFD-FU
Study First Received: September 13, 2005
Last Updated: August 25, 2009
Health Authority: Germany: Federal Office for Radiation Protection

Keywords provided by Technische Universität Dresden:
Radiotherapy
F-18-OMFD

Additional relevant MeSH terms:
Brain Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Neoplasms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on July 28, 2014